The JAK2 V617F mutation induces an inflammatory phenotype mediated by cytokine, chemokine and growth-hormone signaling, thus contributing to inflammation, myeloproliferation, thrombosis development, splenomegaly and constitutional symptom onset in patients with MPN [31,34]. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.